In what could turn out to be its largest acquisition ever, generic drug giant Mylan on Wednesday went public with a bid for competing Ireland-based drugmaker Perrigo Co. in a deal valued at about $30 billion.
The proposal, offering $205 a share in an unspecified combination of cash and stock, was contained in a letter from Mylan chairman Robert Coury delivered to Perrigo CEO Joseph Papa on Monday. Mylan released the letter Wednesday morning.
Mr. Coury’s letter indicated that joining forces with Perrigo would nearly double Mylan’s revenue, which was $7.7 billion in 2014.
Perrigo, based in Dublin, issued a brief statement Wednesday afternoon acknowledging the “unsolicited” proposal, saying, “The board of Perrigo will meet to discuss the proposal and a further announcement will be made when appropriate.”
Full Content: The New York Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
T-Mobile Faces Class-Action Lawsuit Over Sprint Merger After Appeal Denied
May 16, 2024 by
CPI
Google Faces Backlash Over Introduction of AI-Generated Summaries in Searches
May 16, 2024 by
CPI
CMA Launches Phase 2 Probe into AlphaTheta’s Acquisition of Serato
May 16, 2024 by
CPI
NFL Executive Escapes Testifying in High-Stakes Trial Over Televised Games
May 16, 2024 by
CPI
EU Consumers Lodge Complaint Against Chinese Retailer Temu Over Content Rules Breach
May 16, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI